ARWR ARROWHEAD PHARMACEUTICALS, INC.: institutional ownership and insider trading
525 funds reported holding $11.0B of ARROWHEAD PHARMACEUTICALS, INC. in their latest 13F filings; in Q2 2026 funds net sold $106M, with 120 new positions and 57 funds selling out; over the last 12 months insiders bought $0 and sold $37.3M on the open market.
Famous investors holding ARWR
- Renaissance Technologies (Renaissance Technologies): $38.2M, 0.1% of the portfolio
- Two Sigma (Two Sigma Investments): $47.3M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $35.2M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $33.2M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $26.6M, 0.0% of the portfolio
Largest institutional holders of ARWR
- BlackRock, Inc. (BLK) — $1.21B
- VANGUARD GROUP INC — $1.02B
- Avoro Capital Advisors LLC — $926M
- FMR LLC — $655M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $518M
- VANGUARD CAPITAL MANAGEMENT LLC — $498M
- STATE STREET CORP (STT, STT-PG) — $464M
- NORGES BANK — $318M
- Invesco Ltd. (IVZ) — $317M
- GEODE CAPITAL MANAGEMENT, LLC — $299M
Recent ARWR insider trades
- Aug 18, 2026: Perry Michael S sold 11,600 shares ($1.01M)
- Aug 18, 2026: Olukotun Adeoye Y sold 2,000 shares ($174K)
- May 12, 2026: Lu Hongbo sold 2,970 shares ($228K)
- Apr 23, 2026: Hamilton James C sold 10,000 shares ($750K)
5%+ owners
- BlackRock, Inc.: 10.1% (Schedule 13G/A, filed Jul 27, 2026)
- Avoro Capital Advisors LLC: 9.6% (Schedule 13G/A, filed Aug 14, 2026)
- FMR LLC: 5.2% (Schedule 13G, filed May 6, 2026)
- Vanguard Capital Management: 5.1% (Schedule 13G, filed Apr 29, 2026)